Found: 133
Select item for more details and to access through your institution.
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1016, doi. 10.1007/s10637-013-9934-y
- By:
- Publication type:
- Article
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 1, p. 335, doi. 10.1007/s10637-010-9491-6
- By:
- Publication type:
- Article
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 523, doi. 10.1007/s10637-009-9280-2
- By:
- Publication type:
- Article
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 273, doi. 10.1007/s10637-007-9107-y
- By:
- Publication type:
- Article
Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 5, p. 487, doi. 10.1007/s10637-007-9059-2
- By:
- Publication type:
- Article
Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study.
- Published in:
- BJU International, 2024, v. 133, n. 2, p. 169, doi. 10.1111/bju.16125
- By:
- Publication type:
- Article
Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
- Published in:
- BJU International, 2020, v. 126, n. 1, p. 73, doi. 10.1111/bju.15058
- By:
- Publication type:
- Article
Medical Treatment of Advanced Testicular Cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 6, p. 672, doi. 10.1001/jama.299.6.672
- By:
- Publication type:
- Article
Sunitinib in Patients With Metastatic Renal Cell Carcinoma.
- Published in:
- JAMA: Journal of the American Medical Association, 2006, v. 295, n. 21, p. 2516, doi. 10.1001/jama.295.21.2516
- By:
- Publication type:
- Article
Advanced Seminoma: The Role of Chemotherapy and Adjunctive Surgery.
- Published in:
- Annals of Internal Medicine, 1988, v. 108, n. 4, p. 513, doi. 10.7326/0003-4819-108-4-513
- By:
- Publication type:
- Article
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 324, doi. 10.1002/pst.2079
- By:
- Publication type:
- Article
Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this 'adaptive response' in mice.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 65, n. 6, p. 615, doi. 10.1016/S0009-9236(99)90083-8
- By:
- Publication type:
- Article
Novel Targets Therapies for Metastatic Renal Cell Carcinoma and.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 14, p. 1745
- By:
- Publication type:
- Article
Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 7, p. e2422674, doi. 10.1001/jamanetworkopen.2024.22674
- By:
- Publication type:
- Article
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
- Published in:
- Nature Communications, 2016, v. 7, n. 10, p. 13131, doi. 10.1038/ncomms13131
- By:
- Publication type:
- Article
Phase I Clinical Trial with Fractionated Radioimmunotherapy Using <sup>131</sup>I-Labeled Chimeric G250 in Metastatic Renal Cancer.
- Published in:
- Journal of Nuclear Medicine, 2004, v. 45, n. 8, p. 1412
- By:
- Publication type:
- Article
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 20, p. 1558, doi. 10.1093/jnci/djr329
- By:
- Publication type:
- Article
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 9, p. 763, doi. 10.1093/jnci/djr128
- By:
- Publication type:
- Article
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
- Published in:
- 2007
- By:
- Publication type:
- letter
Sunitinib: A Viewpoint by Robert J. Motzer.
- Published in:
- Drugs, 2006, v. 66, n. 17, p. 2267, doi. 10.2165/00003495-200666170-00008
- By:
- Publication type:
- Article
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma.
- Published in:
- Oncology, 2016, v. 90, n. 3, p. 119, doi. 10.1159/000443647
- By:
- Publication type:
- Article
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib.
- Published in:
- Oncology, 2015, v. 89, n. 4, p. 235, doi. 10.1159/000430989
- By:
- Publication type:
- Article
An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 24, p. 1862, doi. 10.1093/jnci/djt310
- By:
- Publication type:
- Article
An evaluation of the role of tumor load in cytoreductive nephrectomy.
- Published in:
- Canadian Urological Association Journal, 2020, v. 14, n. 12, p. E625, doi. 10.5489/cuaj.6350
- By:
- Publication type:
- Article
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
- Published in:
- Oncologist, 2024, v. 29, n. 6, p. 511, doi. 10.1093/oncolo/oyae003
- By:
- Publication type:
- Article
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002.
- Published in:
- Oncologist, 2023, v. 28, p. S10, doi. 10.1093/oncolo/oyad216.016
- By:
- Publication type:
- Article
Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma.
- Published in:
- Oncologist, 2023, v. 28, p. S3, doi. 10.1093/oncolo/oyad216.006
- By:
- Publication type:
- Article
Functional and translational consequences of immunometabolic coevolution in ccRCC.
- Published in:
- Oncologist, 2023, v. 28, p. S1, doi. 10.1093/oncolo/oyad216.003
- By:
- Publication type:
- Article
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. 501, doi. 10.1093/oncolo/oyac269
- By:
- Publication type:
- Article
Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 6, p. 483, doi. 10.1002/onco.13719
- By:
- Publication type:
- Article
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
- Published in:
- Oncologist, 2017, v. 22, n. 1, p. 41, doi. 10.1634/theoncologist.2016-0197
- By:
- Publication type:
- Article
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
- Published in:
- Oncologist, 2016, v. 21, n. 7, p. 787, doi. 10.1634/theoncologist.2016-0145
- By:
- Publication type:
- Article
Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.
- Published in:
- Oncologist, 2011, v. 16, n. 5, p. 632, doi. 10.1634/theoncologist.2010-0299
- By:
- Publication type:
- Article
Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow.
- Published in:
- Oncologist, 2011, v. 16, p. 45, doi. 10.1634/theoncologist.2011-S2-45
- By:
- Publication type:
- Article
New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview.
- Published in:
- Oncologist, 2011, v. 16, p. 1, doi. 10.1634/theoncologist.2011-S2-01
- By:
- Publication type:
- Article
Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow.
- Published in:
- Oncologist, 2011, v. 16, p. 45, doi. 10.1634/theoncologist.2011-S2-45
- By:
- Publication type:
- Article
New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview.
- Published in:
- Oncologist, 2011, v. 16, p. 1, doi. 10.1634/theoncologist.2011-S2-01
- By:
- Publication type:
- Article
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies.
- Published in:
- Oncologist, 2008, v. 13, n. 10, p. 1084, doi. 10.1634/theoncologist.2008-0120
- By:
- Publication type:
- Article
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 6, p. 1485, doi. 10.1002/cam4.293
- By:
- Publication type:
- Article
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 5, p. 1353, doi. 10.1002/cam4.286
- By:
- Publication type:
- Article
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1223282
- By:
- Publication type:
- Article
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-17965-0
- By:
- Publication type:
- Article
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 1, p. 52, doi. 10.1080/0284186X.2021.1995041
- By:
- Publication type:
- Article
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 1, p. 20, doi. 10.1080/0284186X.2019.1656342
- By:
- Publication type:
- Article